Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mary Krinsky

Gastroenterology La Jolla, CA Medical Doctor

NPI 1588765085 CMS profile 71489

9300 Campus Point Dr, La Jolla, CA 92037

Open in the dashboard

General payments

$26,368

118 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Krinsky of La Jolla, CA is reported in the CMS Open Payments database as having received $26,368 across 118 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,890 36
2024 General $1,721 19
2023 General $844 16
2022 General $470 12
2021 General $465 12
2020 General $92 6
2019 General $886 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Krinsky
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Mary Krinsky were reported at $21,890. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Mary Krinsky Gastroenterology median Middle half National median
2019 $886 $417 $126–$1,100 $163
2020 $92 $224 $74–$624 $114
2021 $465 $352 $106–$1,054 $132
2022 $470 $448 $129–$1,270 $149
2023 $844 $533 $150–$1,390 $160
2024 $1,721 $605 $160–$1,606 $164
2025 $21,890 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $19,641 71 payments
  2. Amgen Inc. $3,167 3 payments
  3. Olympus Medical Systems Corporation $1,450 1 payment
  4. Cook Medical LLC $1,352 22 payments
  5. Olympus America Inc. $286 7 payments
  6. CONMED Corporation $158 2 payments
  7. Endogastric Solutions, Inc $119 3 payments
  8. Steris Corporation $51 3 payments
  9. Covidien LP $31 2 payments
  10. Ambu Inc. $30 1 payment
  11. Other $83 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,300 4 payments
  2. Food and Beverage $5,214 99 payments
  3. Consulting Fee $4,485 2 payments
  4. Travel and Lodging $2,342 12 payments
  5. Education $26 1 payment
Products named General payments · program years 2019–2025
  1. General - Therapies $14,521 5 payments
  2. UPLIZNA $3,167 3 payments
  3. SpyGlass $1,520 10 payments
  4. EVIS EXERA III DUODENOVIDEOSCOPE $1,450 1 payment
  5. OverStitch Endoscopic Suturing System $593 4 payments
  6. Hemospray $537 8 payments
  7. EchoTip $400 7 payments
  8. Axios $388 4 payments
  9. GENERAL POLYPECTOMY $358 4 payments
  10. ECHOTIP INSIGHT $283 5 payments
  11. Other $2,227 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

109

Median for Gastroenterology: 569

Drug cost

$110,843

Median for Gastroenterology: $104,976

Branded share of claims

30.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 12 $108,557
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 21 $1,366
Pantoprazole Sodium Generic 35 $528
Famotidine Generic 14 $167
Omeprazole Generic 11 $163
Ciprofloxacin Hcl Generic 16 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$57,659

Medicare's payments for the services billed

Medicare patients

175

Average age 73

Services billed

480

99 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Chronic kidney disease 37%
Diabetes 34%
Cancer 33%
Osteoporosis 29%
Depression 27%
Ischemic heart disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

118 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record